Thrombotic Status Analyser

Summary

A physiologically relevant global in vitro test is described which allows the overall assessment of both thrombotic and thrombolytic activities of blood. In principle, native blood is drawn in pulses through a capillary tube where haemodynamic forces induce a platelet reaction culminating in vessel occlusion. Dislodgement/disintegration of the stabilised thrombus under pressure is a reflection of thrombolysis. Evidence is presented for the platelet-rich nature of the occlusion and that disruption of the thrombus and re-established patency is the result of thrombolysis, that is fibrinolysis with significant contribution from platelets.

This test sensitively detects hypercoagulability (stasis); platelet hyperreactivity (coronary artery disease); anti-platelet effect (aspirin, prostacyclin) and the thrombolytic effect of, thrombin generation by, and resistance to streptokinase. Therefore, this overall assessment of thrombotic status could be of great diagnostic and therapeutic benefit in clinical practice.

• References

• 1 Swan HJ C. Acute myocardial infarction: A failure to timely, spontaneous thrombolysis. JACC 1989; 13: 1435-1437
• 2 Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 351-356
• 3 Braaten JV, Handt S, Jerome WG, Kirkpartick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1; Light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
• 4 Dhall T, Shah G, Ferguson I, Dhall D. Fibrin network structure: Modification by platelets. Thromb Haemost 1983; 49: 42
• 5 Janmey PA, Lamb JA, Ezzell RM, Hvidt S, Lind SE. Effects of actin filaments on fibrin clot structure and lysis. Blood 1992; 80: 928-936
• 6 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arte-rial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 920-928
• 7 Stringer HA R, van SwietenP, eijnen HF, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb 1994; 14: 1452-1458
• 8 Ikeda H, Koga Y, Kuwano K, Nakayama H, Ueno T, Yoshida N, Adachi K, Park IS, Toshima H. Cyclic flow variations in a conscious dog model of coronary artery stenoses and endothelial injury correlate with acute ischemic heart disease syndromes in humans. JACC 1993; 21: 1008-1017
• 9 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992; 326: 242-251
• 10 Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in ste-nosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27
• 11 Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in the late platelet thrombus growth and/or stability. Arterioscler Thromb 1994; 14: 1466-1474
• 12 Strony J, Beaudoin A, Brands D, Adelman B. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol 1993; 265: H1787-H1796
• 13 Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis. Basic principles and applications Thromb Haemost 1986; 55: 415-435
• 14 Glassman A, Abram M, Baxter G, Swett A. Euglobulin lysis times: An update. Ann Clin Lab Science 1993; 23: 329-332
• 15 Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model J clin Invest 1989; 84: 1134-1144
• 16 Brommer EJ P, Meijer P. Thrombin generation induced by the intrinsic or extrinsic coagulation pathway is accelerated by streptokinase, independently of plasminogen. Thromb Haemost 1993; 70: 995-997
• 17 Simoons ML, Arnold AE R. Tailored thrombolytic therapy. Circulation 1993; 88: 2556-2564
• 18 Linderer T, Schröder R, Arntz R, Heineking ML, Wunderlich W, Kohl K, Forycki F, Henzgen R, Wagner J. Prehospital thrombolysis: Beneficial effects of very early treatment on infarct size and left ventricular function. JACC 1993; 22: 1304-1310
• 19 Patel S, Jalihal S, Dutka D P, Morris G K. Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction. Br Heart J 1993; 70: 119-121
• 20 Buchalter MB. Are streptokinase antibodies clinically important? (Editorial). Br Heart J 1993; 70: 101-102
• 21 Vanderschueren SM F, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost 1994; 72: 297-301